Procter & Gamble Health Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: March 8, 2025, 11:04 am

Market Cap	8,732 Cr.
Current Price	5,260
High / Low	5,850/4,637
Stock P/E	35.6
Book Value	368
Dividend Yield	1.52 %
ROCE	45.0 %
ROE	33.5 %
Face Value	10.0
PEG Ratio	5.94

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Procter & Gamble Health Ltd

Competitors of Procter & Gamble Health Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
MPS Pharmaa Ltd	6.71 Cr.	3.51	4.33/3.05		0.80	0.00 %	9.15 %	34.9 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	53.1 Cr.	71.5	94.9/32.1	18.0	11.9	0.00 %	9.72 %	3.44 %	10.0
Gujarat Inject (Kerala) Ltd	38.0 Cr.	26.0	29.0/8.74	38.8	6.64	0.00 %	2.65 %	2.08 %	10.0
Godavari Drugs Ltd	70.4 Cr.	93.5	155/79.0	11.4	55.4	0.00 %	14.4 %	15.5 %	10.0
Industry Average	17,255.37 Cr	1,081.84		42.42	185.80	0.37%	16.00%	16.32%	6.27

All Competitor Stocks of Procter & Gamble Health Ltd

Quarterly Result

Metric	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Sales	278	268	296	298	310	321	301	305	310	252	284	313	310
Expenses	216	199	237	207	201	241	256	216	208	185	236	199	186
Operating Profit	62	69	59	91	109	80	45	89	102	67	48	114	123
OPM %	22%	26%	20%	31%	35%	25%	15%	29%	33%	27%	17%	36%	40%
Other Income	5	2	3	3	5	5	5	6	5	2	-18	3	4
Interest	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	7	6	7	7	8	6	6	6	7	7	7	6	6
Profit before tax	60	65	55	87	105	79	44	88	100	63	23	111	122
Tax %	25%	21%	25%	26%	27%	25%	32%	26%	28%	26%	26%	26%	25%
Net Profit	45	51	41	64	77	59	30	66	72	47	17	82	91
EPS in Rs	27.01	30.82	24.81	38.35	46.27	35.66	17.96	39.50	43.42	28.05	10.11	49.60	54.76

Last Updated: February 28, 2025, 5:40 pm

Below is a detailed analysis of the quarterly data for Procter & Gamble Health Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

For Sales, as of Dec 2024, the value is ₹310.00 Cr.. The value appears to be declining and may need further review. It has decreased from 313.00 Cr. (Sep 2024) to ₹310.00 Cr., marking a decrease of 3.00 Cr..
For Expenses, as of Dec 2024, the value is ₹186.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 199.00 Cr. (Sep 2024) to ₹186.00 Cr., marking a decrease of 13.00 Cr..
For Operating Profit, as of Dec 2024, the value is ₹123.00 Cr.. The value appears strong and on an upward trend. It has increased from 114.00 Cr. (Sep 2024) to ₹123.00 Cr., marking an increase of ₹9.00 Cr..
For OPM %, as of Dec 2024, the value is 40.00%. The value appears strong and on an upward trend. It has increased from 36.00% (Sep 2024) to 40.00%, marking an increase of 4.00%.
For Other Income, as of Dec 2024, the value is ₹4.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Sep 2024) to ₹4.00 Cr., marking an increase of ₹1.00 Cr..
For Interest, as of Dec 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00 Cr..
For Depreciation, as of Dec 2024, the value is ₹6.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 6.00 Cr..
For Profit before tax, as of Dec 2024, the value is ₹122.00 Cr.. The value appears strong and on an upward trend. It has increased from 111.00 Cr. (Sep 2024) to ₹122.00 Cr., marking an increase of ₹11.00 Cr..
For Tax %, as of Dec 2024, the value is 25.00%. The value appears to be improving (decreasing) as expected. It has decreased from 26.00% (Sep 2024) to 25.00%, marking a decrease of 1.00%.
For Net Profit, as of Dec 2024, the value is ₹91.00 Cr.. The value appears strong and on an upward trend. It has increased from 82.00 Cr. (Sep 2024) to ₹91.00 Cr., marking an increase of ₹9.00 Cr..
For EPS in Rs, as of Dec 2024, the value is 54.76. The value appears strong and on an upward trend. It has increased from ₹49.60 (Sep 2024) to 54.76, marking an increase of ₹5.16.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 3:07 pm

Metric	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Jun 2020n n 18m	Jun 2021	Jun 2022	Jun 2023	Jun 2024	TTM
Sales	798	867	940	993	698	849	927	1,356	1,009	1,114	1,230	1,151	1,160
Expenses	721	809	855	877	621	701	723	1,037	762	846	905	845	806
Operating Profit	77	59	85	116	77	148	204	319	246	268	325	307	353
OPM %	10%	7%	9%	12%	11%	17%	22%	24%	24%	24%	26%	27%	30%
Other Income	21	20	22	24	74	768	48	66	18	13	18	-5	-9
Interest	0	0	0	0	0	0	0	0	1	0	1	1	1
Depreciation	10	13	23	25	19	21	17	29	30	27	28	27	25
Profit before tax	88	67	83	115	132	895	234	355	233	253	314	273	319
Tax %	37%	35%	36%	31%	29%	6%	32%	28%	24%	24%	27%	26%
Net Profit	56	43	54	79	94	839	159	254	177	193	229	201	237
EPS in Rs	33.66	26.04	32.27	47.67	56.57	505.27	95.64	153.07	106.51	115.98	138.24	121.08	142.52
Dividend Payout %	25%	23%	23%	23%	27%	87%	0%	150%	122%	45%	69%	215%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year
YoY Net Profit Growth (%)
Change in YoY Net Profit Growth (%)

No data available for trend analysis.

No data available for the compounded sales growth chart.

Balance Sheet

Last Updated: September 15, 2024, 2:57 pm

Month	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024
Equity Capital	17	17	17	17	17	17	17	17	17	17	17	17
Reserves	506	538	575	647	717	1,524	800	890	687	600	734	522
Borrowings	0	0	0	0	0	0	0	0	8	3	12	10
Other Liabilities	125	154	192	215	258	219	250	269	275	269	338	247
Total Liabilities	648	708	784	879	991	1,759	1,067	1,176	986	888	1,101	794
Fixed Assets	85	110	132	111	115	104	101	101	104	112	144	128
CWIP	9	28	7	30	9	17	11	21	39	41	32	6
Investments	24	24	42	28	70	0	0	0	0	0	0	0
Other Assets	530	547	603	711	797	1,639	954	1,053	843	736	925	660
Total Assets	648	708	784	879	991	1,759	1,067	1,176	986	888	1,101	794

Below is a detailed analysis of the balance sheet data for Procter & Gamble Health Ltd based on the most recent figures (Jun 2024) and their trends compared to the previous period:

For Equity Capital, as of Jun 2024, the value is ₹17.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2023) which recorded ₹17.00 Cr..
For Reserves, as of Jun 2024, the value is ₹522.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹734.00 Cr. (Jun 2023) to ₹522.00 Cr., marking a decrease of 212.00 Cr..
For Borrowings, as of Jun 2024, the value is ₹10.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from ₹12.00 Cr. (Jun 2023) to ₹10.00 Cr., marking a decrease of 2.00 Cr..
For Other Liabilities, as of Jun 2024, the value is ₹247.00 Cr.. The value appears to be improving (decreasing). It has decreased from ₹338.00 Cr. (Jun 2023) to ₹247.00 Cr., marking a decrease of 91.00 Cr..
For Total Liabilities, as of Jun 2024, the value is ₹794.00 Cr.. The value appears to be improving (decreasing). It has decreased from ₹1,101.00 Cr. (Jun 2023) to ₹794.00 Cr., marking a decrease of 307.00 Cr..
For Fixed Assets, as of Jun 2024, the value is ₹128.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹144.00 Cr. (Jun 2023) to ₹128.00 Cr., marking a decrease of 16.00 Cr..
For CWIP, as of Jun 2024, the value is ₹6.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹32.00 Cr. (Jun 2023) to ₹6.00 Cr., marking a decrease of 26.00 Cr..
For Investments, as of Jun 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2023) which recorded ₹0.00 Cr..
For Other Assets, as of Jun 2024, the value is ₹660.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹925.00 Cr. (Jun 2023) to ₹660.00 Cr., marking a decrease of 265.00 Cr..
For Total Assets, as of Jun 2024, the value is ₹794.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹1,101.00 Cr. (Jun 2023) to ₹794.00 Cr., marking a decrease of 307.00 Cr..

Notably, the Reserves (₹522.00 Cr.) exceed the Borrowings (10.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

No data available for this post.

Free Cash Flow

Month	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Jun 2020n n 18m	Jun 2021	Jun 2022	Jun 2023	Jun 2024
Free Cash Flow	77.00	59.00	85.00	116.00	77.00	148.00	204.00	319.00	238.00	265.00	313.00	297.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024
Debtor Days	38	44	49	39	64	28	30	26	22	27	34	27
Inventory Days	153	162	140	145	243	154	139	113	138	124	136	120
Days Payable	37	40	55	67	128	124	106	105	209	185	239	184
Cash Conversion Cycle	154	166	134	118	179	58	63	34	-49	-34	-69	-37
Working Capital Days	70	74	69	52	94	42	22	23	9	18	16	20
ROCE %	18%	12%	15%	18%	16%	78%	20%	29%	29%	38%	45%	45%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoters	51.82%	51.82%	51.82%	51.82%	51.82%	51.82%	51.82%	51.82%	51.82%	51.82%	51.82%	51.82%
FIIs	5.97%	6.57%	6.47%	6.05%	6.33%	6.72%	7.15%	7.38%	7.60%	6.24%	6.39%	6.61%
DIIs	8.53%	7.91%	8.07%	12.62%	12.44%	12.31%	12.29%	12.30%	12.66%	13.72%	14.56%	14.84%
Public	33.69%	33.71%	33.64%	29.51%	29.41%	29.14%	28.74%	28.50%	27.92%	28.22%	27.24%	26.74%
No. of Shareholders	65,537	66,289	65,729	65,148	63,831	61,030	58,856	57,919	56,730	56,778	55,923	54,792

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
Nippon India Small Cap Fund	596,807	0.75	306.1	28,800	2025-03-11	1972.25%
HDFC Small Cap Fund - Regular Plan	326,834	0.66	167.63	28,800	2025-03-11	1034.84%
DSP Healthcare Fund	158,704	4.23	81.4	28,800	2025-03-11	451.06%
UTI MNC Fund	145,887	2.83	74.82	28,800	2025-03-11	406.55%
Sundaram Small Cap Fund	74,554	1.33	38.24	28,800	2025-03-11	158.87%
UTI Healthcare Fund	35,000	2.1	17.95	28,800	2025-03-11	21.53%
Tata Retirement Savings Fund - Moderate Plan - Regular Plan	31,000	0.86	15.9	28,800	2025-03-11	7.64%
Tata Retirement Savings Fund - Progressive Plan - Regular Plan	28,800	0.91	14.77	28,800	2025-03-11	0%
Tata India Pharma & HealthCare Fund	16,000	1.09	8.21	28,800	2025-03-11	-44.44%
Aditya Birla Sun Life MNC Fund - Div	13,671	0.2	7.01	28,800	2025-03-11	-52.53%

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Jun 24	Jun 23	Jun 22	Jun 21	Jun 20
FaceValue	10.00	10.00	10.00	10.00	10.00
Basic EPS (Rs.)	121.07	138.00	116.00	107.00	153.00
Diluted EPS (Rs.)	121.07	138.00	116.00	107.00	153.00
Cash EPS (Rs.)	137.58	155.16	132.29	124.60	170.80
Book Value[Excl.RevalReserv]/Share (Rs.)	324.24	452.34	371.38	423.92	545.99
Book Value[Incl.RevalReserv]/Share (Rs.)	324.24	452.34	371.38	423.92	545.99
Dividend / Share (Rs.)	260.00	95.00	52.50	130.00	230.00
Revenue From Operations / Share (Rs.)	693.53	740.73	671.33	607.67	816.78
PBDIT / Share (Rs.)	193.75	206.67	169.20	159.11	231.51
PBIT / Share (Rs.)	177.25	189.74	152.88	141.01	213.76
PBT / Share (Rs.)	164.65	189.28	152.63	140.53	213.76
Net Profit / Share (Rs.)	121.07	138.23	115.97	106.51	153.06
PBDIT Margin (%)	27.93	27.90	25.20	26.18	28.34
PBIT Margin (%)	25.55	25.61	22.77	23.20	26.17
PBT Margin (%)	23.74	25.55	22.73	23.12	26.17
Net Profit Margin (%)	17.45	18.66	17.27	17.52	18.73
Return on Networth / Equity (%)	37.34	30.55	31.22	25.12	28.03
Return on Capital Employeed (%)	51.13	39.50	38.57	31.32	37.41
Return On Assets (%)	25.30	20.83	21.54	17.92	21.61
Asset Turnover Ratio (%)	1.21	1.23	1.19	0.93	0.00
Current Ratio (X)	2.39	2.62	2.60	3.04	4.21
Quick Ratio (X)	1.90	2.18	2.11	2.55	3.62
Inventory Turnover Ratio (X)	2.38	2.55	2.77	2.29	0.00
Dividend Payout Ratio (NP) (%)	0.00	40.87	147.43	215.93	287.45
Dividend Payout Ratio (CP) (%)	0.00	36.41	129.25	184.57	257.59
Earning Retention Ratio (%)	0.00	59.13	-47.43	-115.93	-187.45
Cash Earning Retention Ratio (%)	0.00	63.59	-29.25	-84.57	-157.59
Interest Coverage Ratio (X)	446.71	445.55	668.74	330.15	0.00
Interest Coverage Ratio (Post Tax) (X)	308.18	299.01	459.38	222.00	0.00
Enterprise Value (Cr.)	8138.39	8273.45	6626.39	8817.13	6112.46
EV / Net Operating Revenue (X)	7.07	6.73	5.95	8.74	4.51
EV / EBITDA (X)	25.30	24.12	23.59	33.38	15.91
MarketCap / Net Operating Revenue (X)	7.28	7.09	6.24	9.21	4.98
Retention Ratios (%)	0.00	59.12	-47.43	-115.93	-187.45
Price / BV (X)	15.57	11.60	11.28	13.20	7.45
Price / Net Operating Revenue (X)	7.28	7.09	6.24	9.21	4.98
EarningsYield	0.02	0.02	0.02	0.01	0.03

After reviewing the key financial ratios for Procter & Gamble Health Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Jun 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Jun 23) which recorded 10.00.
For Basic EPS (Rs.), as of Jun 24, the value is 121.07. This value is within the healthy range. It has decreased from 138.00 (Jun 23) to 121.07, marking a decrease of 16.93.
For Diluted EPS (Rs.), as of Jun 24, the value is 121.07. This value is within the healthy range. It has decreased from 138.00 (Jun 23) to 121.07, marking a decrease of 16.93.
For Cash EPS (Rs.), as of Jun 24, the value is 137.58. This value is within the healthy range. It has decreased from 155.16 (Jun 23) to 137.58, marking a decrease of 17.58.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Jun 24, the value is 324.24. It has decreased from 452.34 (Jun 23) to 324.24, marking a decrease of 128.10.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Jun 24, the value is 324.24. It has decreased from 452.34 (Jun 23) to 324.24, marking a decrease of 128.10.
For Dividend / Share (Rs.), as of Jun 24, the value is 260.00. This value exceeds the healthy maximum of 3. It has increased from 95.00 (Jun 23) to 260.00, marking an increase of 165.00.
For Revenue From Operations / Share (Rs.), as of Jun 24, the value is 693.53. It has decreased from 740.73 (Jun 23) to 693.53, marking a decrease of 47.20.
For PBDIT / Share (Rs.), as of Jun 24, the value is 193.75. This value is within the healthy range. It has decreased from 206.67 (Jun 23) to 193.75, marking a decrease of 12.92.
For PBIT / Share (Rs.), as of Jun 24, the value is 177.25. This value is within the healthy range. It has decreased from 189.74 (Jun 23) to 177.25, marking a decrease of 12.49.
For PBT / Share (Rs.), as of Jun 24, the value is 164.65. This value is within the healthy range. It has decreased from 189.28 (Jun 23) to 164.65, marking a decrease of 24.63.
For Net Profit / Share (Rs.), as of Jun 24, the value is 121.07. This value is within the healthy range. It has decreased from 138.23 (Jun 23) to 121.07, marking a decrease of 17.16.
For PBDIT Margin (%), as of Jun 24, the value is 27.93. This value is within the healthy range. It has increased from 27.90 (Jun 23) to 27.93, marking an increase of 0.03.
For PBIT Margin (%), as of Jun 24, the value is 25.55. This value exceeds the healthy maximum of 20. It has decreased from 25.61 (Jun 23) to 25.55, marking a decrease of 0.06.
For PBT Margin (%), as of Jun 24, the value is 23.74. This value is within the healthy range. It has decreased from 25.55 (Jun 23) to 23.74, marking a decrease of 1.81.
For Net Profit Margin (%), as of Jun 24, the value is 17.45. This value exceeds the healthy maximum of 10. It has decreased from 18.66 (Jun 23) to 17.45, marking a decrease of 1.21.
For Return on Networth / Equity (%), as of Jun 24, the value is 37.34. This value is within the healthy range. It has increased from 30.55 (Jun 23) to 37.34, marking an increase of 6.79.
For Return on Capital Employeed (%), as of Jun 24, the value is 51.13. This value is within the healthy range. It has increased from 39.50 (Jun 23) to 51.13, marking an increase of 11.63.
For Return On Assets (%), as of Jun 24, the value is 25.30. This value is within the healthy range. It has increased from 20.83 (Jun 23) to 25.30, marking an increase of 4.47.
For Asset Turnover Ratio (%), as of Jun 24, the value is 1.21. It has decreased from 1.23 (Jun 23) to 1.21, marking a decrease of 0.02.
For Current Ratio (X), as of Jun 24, the value is 2.39. This value is within the healthy range. It has decreased from 2.62 (Jun 23) to 2.39, marking a decrease of 0.23.
For Quick Ratio (X), as of Jun 24, the value is 1.90. This value is within the healthy range. It has decreased from 2.18 (Jun 23) to 1.90, marking a decrease of 0.28.
For Inventory Turnover Ratio (X), as of Jun 24, the value is 2.38. This value is below the healthy minimum of 4. It has decreased from 2.55 (Jun 23) to 2.38, marking a decrease of 0.17.
For Dividend Payout Ratio (NP) (%), as of Jun 24, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 40.87 (Jun 23) to 0.00, marking a decrease of 40.87.
For Dividend Payout Ratio (CP) (%), as of Jun 24, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 36.41 (Jun 23) to 0.00, marking a decrease of 36.41.
For Earning Retention Ratio (%), as of Jun 24, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 59.13 (Jun 23) to 0.00, marking a decrease of 59.13.
For Cash Earning Retention Ratio (%), as of Jun 24, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 63.59 (Jun 23) to 0.00, marking a decrease of 63.59.
For Interest Coverage Ratio (X), as of Jun 24, the value is 446.71. This value is within the healthy range. It has increased from 445.55 (Jun 23) to 446.71, marking an increase of 1.16.
For Interest Coverage Ratio (Post Tax) (X), as of Jun 24, the value is 308.18. This value is within the healthy range. It has increased from 299.01 (Jun 23) to 308.18, marking an increase of 9.17.
For Enterprise Value (Cr.), as of Jun 24, the value is 8,138.39. It has decreased from 8,273.45 (Jun 23) to 8,138.39, marking a decrease of 135.06.
For EV / Net Operating Revenue (X), as of Jun 24, the value is 7.07. This value exceeds the healthy maximum of 3. It has increased from 6.73 (Jun 23) to 7.07, marking an increase of 0.34.
For EV / EBITDA (X), as of Jun 24, the value is 25.30. This value exceeds the healthy maximum of 15. It has increased from 24.12 (Jun 23) to 25.30, marking an increase of 1.18.
For MarketCap / Net Operating Revenue (X), as of Jun 24, the value is 7.28. This value exceeds the healthy maximum of 3. It has increased from 7.09 (Jun 23) to 7.28, marking an increase of 0.19.
For Retention Ratios (%), as of Jun 24, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 59.12 (Jun 23) to 0.00, marking a decrease of 59.12.
For Price / BV (X), as of Jun 24, the value is 15.57. This value exceeds the healthy maximum of 3. It has increased from 11.60 (Jun 23) to 15.57, marking an increase of 3.97.
For Price / Net Operating Revenue (X), as of Jun 24, the value is 7.28. This value exceeds the healthy maximum of 3. It has increased from 7.09 (Jun 23) to 7.28, marking an increase of 0.19.
For EarningsYield, as of Jun 24, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Jun 23) which recorded 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Procter & Gamble Health Ltd as of March 12, 2025 is: ₹3,564.38

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 12, 2025, Procter & Gamble Health Ltd is Overvalued by 32.24% compared to the current share price 5,260.00

Intrinsic Value of Procter & Gamble Health Ltd as of March 12, 2025 is: 3,778.17

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 12, 2025, Procter & Gamble Health Ltd is Overvalued by 28.17% compared to the current share price 5,260.00

Last 5 Year EPS CAGR: 6.00%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a high average ROCE of 30.25%, which is a positive sign. The company has higher reserves (728.33 cr) compared to borrowings (2.75 cr), indicating strong financial stability. The company has shown consistent growth in sales (467.54 cr) and profit (258.54 cr) over the years.	The stock has a high average Working Capital Days of 42.42, which may not be favorable. The stock has a high average Cash Conversion Cycle of 59.75, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Procter & Gamble Health Ltd:
1. Net Profit Margin: 17.45%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 51.13% (Industry Average ROCE: 16%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 37.34% (Industry Average ROE: 16.32%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 308.18
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 1.9
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 35.6 (Industry average Stock P/E: 42.42)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Procter & Gamble Health Ltd. is a Public Limited Listed company incorporated on 26/04/1967 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L99999MH1967PLC013726 and registration number is 013726. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company's Total Operating Revenue is Rs. 1151.26 Cr. and Equity Capital is Rs. 16.60 Cr. for the Year ended 30/06/2024.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	P&G Plaza, Cardinal Gracias Road, Mumbai Maharashtra 400099	investorgrievance.im@pg.com https://www.pghealthindia.com

Management
Name	Position Held
Mr. Suresh Talwar	Chairman & Ind.Director
Mr. Milind Thatte	Managing Director
Mr. Lokesh Chandak	Executive Director & CFO
Ms. Seema Sambasivan	Non Executive Director
Mr. Aalok Agrawal	Non Executive Director
Mrs. Rani Jadhav	Independent Director
Mr. S Madhavan	Independent Director

FAQ

What is the latest intrinsic value of Procter & Gamble Health Ltd?

The latest intrinsic value of Procter & Gamble Health Ltd as on 12 March 2025 is ₹3564.38, which is 32.24% lower than the current market price of 5,260.00, indicating the stock is overvalued by 32.24%. The intrinsic value of Procter & Gamble Health Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹8,732 Cr. and recorded a high/low of ₹5,850/4,637 during the current fiscal year 2024-2025. As of Jun 2024, the company has reserves of ₹522 Cr and total liabilities of ₹794 Cr.

What is the Market Cap of Procter & Gamble Health Ltd?

The Market Cap of Procter & Gamble Health Ltd is 8,732 Cr..

What is the current Stock Price of Procter & Gamble Health Ltd as on 12 March 2025?

The current stock price of Procter & Gamble Health Ltd as on 12 March 2025 is ₹5,260.

What is the High / Low of Procter & Gamble Health Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Procter & Gamble Health Ltd stocks is ₹5,850/4,637.

What is the Stock P/E of Procter & Gamble Health Ltd?

The Stock P/E of Procter & Gamble Health Ltd is 35.6.

What is the Book Value of Procter & Gamble Health Ltd?

The Book Value of Procter & Gamble Health Ltd is 368.

What is the Dividend Yield of Procter & Gamble Health Ltd?

The Dividend Yield of Procter & Gamble Health Ltd is 1.52 %.

What is the ROCE of Procter & Gamble Health Ltd?

The ROCE of Procter & Gamble Health Ltd is 45.0 %.

What is the ROE of Procter & Gamble Health Ltd?

The ROE of Procter & Gamble Health Ltd is 33.5 %.

What is the Face Value of Procter & Gamble Health Ltd?

The Face Value of Procter & Gamble Health Ltd is 10.0.